BioIntercept is pioneering new frontiers in ophthalmology by harnessing our proprietary exosome platform to address the root causes of vision loss. Our research is intensely focused on developing therapies capable of crossing the blood-retinal barrier to deliver neuroprotective and regenerative agents directly to affected tissues. By modulating inflammatory responses and protecting vital retinal cells, we are developing novel approaches for diseases like glaucoma and macular degeneration. This work is critical for creating a new generation of treatments aimed not just at slowing progression, but at preserving and potentially restoring sight.
Our exosome-based platform shows significant promise in pulmonary indications where inflammation, epithelial injury, and immune dysregulation play central roles: